276027
Mortality for aortic aneurysm in the korean population : 5–15 years follow-up
Mortality for aortic aneurysm in the korean population : 5–15 years follow-up
Sunday, November 3, 2013
The objective of this study is to analyze long-term survival of the subjects with aortic aneurysm (AA). The sample included 294 Korean patients aged ≥30 years who were hospitalized from 1994 through 2004. 294 AA subjects (54 in affected coronary artery disease (CAD) and 240 in non-CAD; 223 in AA including abdominal only (AAA) and 71 in AA including thoracic (TAA)) had confirmed by computed tomography angiography in Cardiac & Vascular Center, Samsung Medical Center. Mortality data were obtained from all participants between 1994 and 2009 from the Statistics Korea. All-cause mortality was measured at 5 to15 years. The mean age (years) of AA in CAD subjects was 68.7 (±6.4) and that of AA in non-CAD subjects was 66.5 (±11.3) (p=NS). During the 5 to 15 years follow-up, all-cause cumulative mortality rate was 12.9% in CAD and 15.8% in non-CAD (Fig A). All-cause cumulative mortality rate by AA affected site was 18.3% in TAA and 14.4% in AAA (Fig B). The mean survival time was 6.18 (±0.16) years in CAD and 7.40 (±0.12) years in non-CAD. The mean survival time by AA affected site was 7.92 (±3.32) years in TAA and 7.90 (±3.15) years in AAA. The independent predictors of mortality were included, but not limited to, age, smoking and AA affected site. In this study, we found that cardiovascular risk factors contributed to mortality. And, it seems that there is similarity between CAD and non-CAD in AA, and between TAA and AAA by AA affected site for their mortality rate.
Learning Areas:
Chronic disease management and preventionEpidemiology
Learning Objectives:
Demonstrate long-term survival of aortic aneurysm patients in Korea.
Keywords: Cardiorespiratory, Mortality
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: NA
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
Back to: 2026.0: Chronic Disease Epidemiology Poster Session 1